Fintepla

Active Ingredient(s): Fenfluramine Hydrochloride
FDA Approved: * June 25, 2020
Pharm Company: * ZOGENIX INC
Category: Diet / Weight Loss

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Fintepla Overview

Fenfluramine, sold under the brand name Fintepla, is a medication used for the treatment of seizures associated with Dravet syndrome in people age two and older.[2] The most common adverse reactions include decreased appetite; drowsiness, sedation and lethargy; diarrhea; constipation; abnormal echocardiogram; fatigue or lack of energy; ataxia (lack of coordination), balance disorder, gait disturbance (trouble with walking); increased blood pressure; drooling, salivary hypersec...

Read more Fintepla Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fenfluramine

Recent Fintepla Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fenfluramine Hydrochloride
  • Solution: 2.2mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Fintepla: (1 result)

Sorted by National Drug Code
  • 43376-322 Fintepla 2.2 mg/ml Oral Solution by Zogenix, Inc.

Other drugs which contain Fenfluramine Hydrochloride or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 4 December 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA